Minister for Children, Disability and Equality Norma Foley TD pictured at the new Astellas factory in Tralee. Included in the photo are, Tetsuya Kawasako, Head of Pharma Manufacturing & President of AICL, Mary Buckley, Executive Director, IDA Ireland, Ray O’Connor, Head of Regions, IDA Ireland, Suzanne Geraghty, Head of Astellas Dublin Plant, Emily Ging, Head of Pharma Manufacturing Finance, Louis Collins, Head of Astellas Kerry Plant, Caroline Mullins, Head of Astellas International Business, Dee Moran, Project Manager, IDA Ireland, Owen Moore, Head of Astellas Tralee Plant, Peter Carney, Astellas Market Access and Government Affairs Lead Ireland, Jennifer McHugh, Astellas Communications Business Partner, R&D, Suzanne Geraghty, Head of Astellas Dublin Plant, Emily Ging, Head of Pharma Manufacturing Finance. Photo: Don MacMonagleASTELLAS Ireland Co. Ltd this morning announced an expansion of its biopharmaceutical manufacturing facility at the Kerry Technology Park in Tralee.
The investment will support the installation of a second aseptic filling line and associated manufacturing infrastructure, representing the next phase of development at the site, building upon the successful foundation established with the site’s groundbreaking in March 2024.
The project will double drug product manufacturing capacity at the Tralee facility, creating additional highly skilled roles across engineering, production, quality, logistics and support functions by 2029.
Continued below…
This follows the company’s previously announced €330 million investment in a new state-of-the-art biopharmaceutical facility and second Kerry facility in 2023. The new Kerry facility is scheduled to officially open the doors in early 2027.
This project is supported by the Irish Government through IDA Ireland. The Tralee facility will manufacture medicines for global markets and is designed to support additional products from Astellas’ development pipeline as they progress towards commercialisation.
Tetsuya Kawasko-San, Global Head of Pharma Manufacturing, President of Astellas Ireland Co LTD said: “Astellas has a proud and long-established presence in Ireland, with our operations supporting the reliable supply of medicines to patients around the world. The continued development of our Tralee facility reflects our confidence in Ireland, in the region and in the talented people who will bring this state-of-the-art facility to life. This expansion is a planned continuation of our original investment in Tralee. It enables us to build additional capability into the facility in a phased and disciplined way, responding to an evolving portfolio and patient needs while making the best use of the infrastructure already being developed. We greatly value the continued support of IDA Ireland and our local partners, and we look forward to building on that partnership as Tralee becomes an important part of Astellas’ global manufacturing network.”
To explore career opportunities with Astellas, please visit Tralee – Astellas Jobs.
